An 8 week extension to a randomized, double-blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus and amlodipine treatment strategy in achieving blood pressure control in patients with stage 1 or stage 2 hypertension or uncontrolled on present monotherapy.

Trial Profile

An 8 week extension to a randomized, double-blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus and amlodipine treatment strategy in achieving blood pressure control in patients with stage 1 or stage 2 hypertension or uncontrolled on present monotherapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Amlodipine (Primary) ; Valsartan (Primary) ; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 May 2011 Status changed from completed to recruiting as reported by European Clinical Trials Database record.
    • 10 May 2011 New source identified and integrated (European Clinical Trials Database record EudraCT2005-001258-26 ).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top